Jump Financial LLC Has $5.48 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Jump Financial LLC increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 174.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 139,280 shares of the company's stock after acquiring an additional 88,448 shares during the period. Jump Financial LLC owned approximately 0.16% of CRISPR Therapeutics worth $5,482,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CRSP. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after buying an additional 1,474,439 shares during the period. Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after acquiring an additional 10,579 shares during the last quarter. Geode Capital Management LLC grew its position in CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after acquiring an additional 35,196 shares during the period. Norges Bank acquired a new stake in CRISPR Therapeutics during the fourth quarter worth about $17,458,000. Finally, Contrarius Group Holdings Ltd acquired a new stake in CRISPR Therapeutics during the fourth quarter worth about $14,516,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares of the company's stock, valued at $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,381 shares of company stock valued at $1,608,243. Corporate insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Morgan Stanley boosted their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research note on Friday, February 14th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, March 21st. Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Citigroup decreased their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Finally, Barclays lifted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics has an average rating of "Hold" and a consensus target price of $73.11.

CRISPR Therapeutics Stock Down 0.0 %

CRSP stock traded down $0.01 during trading on Friday, reaching $37.77. 1,027,190 shares of the company's stock were exchanged, compared to its average volume of 1,631,291. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The firm has a market cap of $3.24 billion, a PE ratio of -8.64 and a beta of 1.85. The company's fifty day moving average price is $40.93 and its 200-day moving average price is $43.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.